MAZZERA, Laura
 Distribuzione geografica
Continente #
EU - Europa 307
NA - Nord America 233
AS - Asia 104
AF - Africa 6
Totale 650
Nazione #
US - Stati Uniti d'America 230
IT - Italia 174
SE - Svezia 47
CN - Cina 42
IE - Irlanda 38
SG - Singapore 22
JP - Giappone 18
DE - Germania 13
AT - Austria 10
VN - Vietnam 8
TR - Turchia 7
CI - Costa d'Avorio 6
IN - India 5
BE - Belgio 4
CZ - Repubblica Ceca 4
CA - Canada 3
NL - Olanda 3
RO - Romania 3
BG - Bulgaria 2
DK - Danimarca 2
ES - Italia 2
FI - Finlandia 2
GB - Regno Unito 2
IR - Iran 2
CH - Svizzera 1
Totale 650
Città #
Ann Arbor 58
Parma 47
Dublin 38
Chandler 29
Ashburn 27
Bologna 18
Tokyo 18
Boardman 17
Singapore 15
Falls Church 14
Shanghai 10
Vienna 9
Dong Ket 8
Beijing 7
Bremen 7
Milan 7
Wilmington 7
Abidjan 6
Arzano 6
Piacenza 6
Redmond 6
Princeton 5
Verona 5
Brussels 4
Izmir 4
Jinan 4
Langhirano 4
New York 4
Novara 4
Reggio Emilia 4
Savignano Sul Rubicone 4
Focsani 3
Kocaeli 3
Modena 3
Munich 3
Nanjing 3
Reggio Nell'emilia 3
Santa Clara 3
Seattle 3
Toronto 3
Woodbridge 3
Amsterdam 2
Cremona 2
Frederiksberg 2
Fremont 2
Gurgaon 2
Guwahati 2
Helsinki 2
Inzago 2
Jiaxing 2
Los Angeles 2
Madrid 2
Marghera 2
Mountain View 2
Norwalk 2
Olomouc 2
Padova 2
Redwood City 2
Sala Baganza 2
San Mateo 2
Treviso 2
Abbiategrasso 1
Ahmedabad 1
Ardabil 1
Bari 1
Brno 1
Böblingen 1
Cambridge 1
Council Bluffs 1
Dallas 1
Dearborn 1
Des Moines 1
Fidenza 1
Haikou 1
Hangzhou 1
Hefei 1
Krimpen Aan Den Ijssel 1
Lanzhou 1
Monza 1
Nanchang 1
Palermo 1
Petilia Policastro 1
Pontedera 1
Prilly 1
Puxian 1
Shenyang 1
Sorbolo 1
Springfield 1
Taiyuan 1
Urbino 1
Washington 1
Zhengzhou 1
Totale 503
Nome #
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma 201
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH+-LEUKEMIA 125
The Pharmacological Blockade of Phosphodiesterase IV Potentiates the Anti-Tumor Effects of Arsenic Trioxide (ATO) in Acute Myelogenous Leukemia Cells through Multiple Signaling Pathways 125
MEK1/2 KINASES DISABLE THE TUMOR SUPPRESSOR FUNCTIONS OF NATIVE BCR AND ABL1 KINASES TO IMPAIR ANTICANCER DRUGS’ RESPONSIVENESS IN TKI-RESISTANT PHILADELPHIA POSITIVE LEUKEMIAS 55
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia 53
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 40
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting 34
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH plus -LEUKEMIA 32
Totale 665
Categoria #
all - tutte 2.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.697


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202075 0 0 0 1 2 12 12 7 9 16 9 7
2020/2021109 1 3 4 1 22 15 3 8 24 10 6 12
2021/202269 3 7 0 10 4 6 7 7 6 2 11 6
2022/2023156 13 15 13 11 25 13 2 6 46 4 6 2
2023/2024159 13 8 10 5 25 22 11 3 4 12 12 34
2024/202571 36 18 12 5 0 0 0 0 0 0 0 0
Totale 665